丙型肝炎治疗药物特拉匹韦的药理及临床评价  

Pharmacology and clinical evaluation of telaprevir, a therapeutic drug for hepatitis C virus

作　　者：林惠武[1] 李彩霞[2] 

机构地区：[1]厦门大学附属第一医院思明分院药剂科,厦门361003 [2]厦门大学附属第一医院药学部,厦门361003

出　　处：《中国新药杂志》2012年第24期2844-2847,共4页Chinese Journal of New Drugs

摘　　要：2011年5月23日,美国FDA批准特拉匹韦(telaprevir)用于成人慢性丙型肝炎的治疗。本品可用于未接受过干扰素类药物治疗或对之前的药物治疗无效的患者。特拉匹韦被批准与聚乙二醇干扰素α及利巴韦林联用。其最常见的不良反应是皮疹和贫血等。本文对特拉匹韦的药理作用、药代动力学、临床评价、适应症、用法用量和安全性等进行介绍。The US Food and Drug Administration approved telaprevir used for the treatment of chronic hepatitis C in adults on May 23,2011.Telaprevir can be used for the patients who have not received the treatment of interferon or have no response to the drug before.The most common adverse reactions of telaprevir are skin rash and anemia.The pharmacology,pharmacokinetics,clinical evaluation,indication and usage,and safety of telaprevir were reviewed in this paper.

关 键 词：特拉匹韦 慢性丙型肝炎 药理作用 药代动力学 临床评价 

分 类 号：R975.4[医药卫生—药品]